IST NAZL STUDIO & CURA TUMORI,DIV MED ONCOL B,I-20133 MILAN,ITALY. OSPED S MARIA GORETTI,CTR ONCOL G PORFIRI,LATINA,ITALY.
Oncol Rep. 1995 Jul;2(4):601-2. doi: 10.3892/or.2.4.601.
The incidence of stage IV breast cancer at diagnosis is low, representing about 8% of all new cases. We report on the results obtained with a new aromatase inhibitor, formestane (500 mg i.m. fortnightly), given as a first treatment to fifteen postmenopausal patients with metastatic breast cancer. The overall response rate was 40%, with one complete remission in a patient with soft tissue and bone lesions and five partial remissions. The drug was well. tolerated and no significant systemic or local side effects were observed. We conclude that first treatment of stage IV breast cancer appears to be feasible with a hormonal drug such as formestane.
诊断时 IV 期乳腺癌的发病率较低，约占所有新发病例的 8%。我们报告了一种新的芳香酶抑制剂，依西美坦（500mg，肌内注射，每两周一次）作为转移性乳腺癌 15 例绝经后患者的一线治疗的结果。总的缓解率为 40%，1 例软组织和骨病变的患者完全缓解，5 例部分缓解。该药物耐受性良好，未观察到明显的全身或局部副作用。我们的结论是，用依西美坦等激素药物治疗 IV 期乳腺癌似乎是可行的。
